Medicus Pharma Ltd. Common Stock (MDCX)
MDCX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MDCX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001997296 |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "This uncertainty, together with the Company's continued losses and outstanding debt obligations, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued." | 10-Q 2026-11-06 |
| Cash and burn | $5.0M cash; operating cash flow -$9.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,922,837 (2026-11-02); 22,029,144 a year earlier. 1y figure adjusted for split (1-for-50 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-10-12 | Source 2026-10-12 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-02 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-10-23 |
| Auditor | KPMG LLP, New York, New York, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$15.2M | -$15.9M | $5.0M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | -$11.6M | -$7.0M | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$9.0M | -$9.0M | $6.4M | $2.3M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$15.1M | -$6.6M | $8.7M | $5.2M | Needs four quarters | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | Not filed | -$20.9M | -$6.8M | $8.7M | $6.8M | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$6.2M | -$5.5M | $9.7M | $4.7M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$5.1M | -$3.9M | $4.0M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$3.5M | -$3.2M | $4.2M | $0 | Needs four quarters | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.3% |
| 1 month | -40.5% |
| 3 months | -89.0% |
| Year to date | -97.5% |
| 1 year | -98.3% |
| From 52-week high | -98.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| MDCXW | Medicus Pharma Ltd. Warrant | $0.2000 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier